Gri Bio Inc is a biotechnology company focused on developing innovative therapies to enhance the immune response and improve the treatment of various diseases
The company leverages its proprietary technology platform to identify and create novel biopharmaceutical products aimed at addressing unmet medical needs in areas such as immunology and oncology. By harnessing the power of the immune system, Gri Bio strives to deliver breakthrough treatments that can significantly impact patient outcomes and contribute to advancements in modern medicine.
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board).
